Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

of common stock during the quarter pursuant to a private placement transaction and the issuance of 9,240,307 shares of common stock pursuant to a registered direct offering of common stock during the first quarter of 2008, while the per share amount for the first quarter of 2008 includes only the effect of the 2008 common stock issuance.

As of March 31, 2009, Cadence held cash and cash equivalents of $118.5 million, which included proceeds from the private placement of the company's common stock completed in February 2009, pursuant to which Cadence issued and sold approximately 12.0 million shares at a price of $7.13 per share and 6.0 million warrants, exercisable at $7.84 per share, at a price of $0.125 per warrant. The transaction resulted in proceeds, net of offering costs, of approximately $86.2 million.

Operating expenses for the first quarter ended March 31, 2009 were $10.1 million, a decrease of $3.7 million from the $13.8 million reported for the first quarter of 2008. This decrease was due to a reduction in research and development expenses during the three months ended March 31, 2009, as compared to the same period in 2008, partially offset by restructuring charges incurred as a result of the discontinuation of the company's Omigard development program in the first quarter of 2009. The reduction in research and development costs was primarily the result of reduced clinical research spending due to the completion of the company's clinical trials and reduced charges related to facility improvements at the company's contract manufacturer's facility. Partially offsetting these decreases were increases in costs incurred in preparing for the submission of the company's NDA for Acetavance.

Conference Call and Webcast on May 7, 2009 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time)

Cadence management will host a conference call on May 7, 2009 at 1:30 p.m. Pacific Time (4:30 p.m
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
2. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)...  MiMedx Group, Inc. (NASDAQ: MDXG ), the ... patent-protected processes to develop and market advanced products and ... Medicine, Ophthalmic and Dental sectors of healthcare, announced today ... Annual Canaccord|Genuity Growth Conference in Boston, Massachusetts ... William C. Taylor , President and COO, and ...
(Date:8/3/2015)... Medical, Inc. (Nasdaq: AEMD ), the pioneer in ... announced that it will host its First Quarter Fiscal ... 13, 2015 at 4:30 p.m. Eastern Time. ... fiscal 2016 first quarter results.  A recorded version of ... the call at the Investor Relations portion of the ...
(Date:8/3/2015)... VANCOUVER, BC , Aug. 3, 2015 /PRNewswire/ - RepliCel ... regenerative medicine company focused on the development of autologous cell ... will be presenting at the InvestMNT conference held in ... at 8:15 AM local time. Hall,s presentation will highlight RepliCel,s ... for sale in Europe , clinical data ...
(Date:7/31/2015)... KONG , July 31, 2015 China ... China,s leading provider of cord ... stem cell storage services, today announced that the Company ... the U.S. Securities and Exchange Commission. The filed Form ... ended March 31, 2015. The Form 20-F can be ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... Stem Cell Treatments -- SHENZHEN, China, Sept. 2 /PRNewswire-Asia/ -- ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... everything from antibacterial socks to medical imaging to ... health and safety risks of these particles also ... and Technology (NIST) have developed a simple process ... certain physical and chemical properties that affect how ...
... ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS... -- YOKOHAMA, Japan, September 1, ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Biology Technology:New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 2New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 3New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 4New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 5New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 6New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 7New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments 8The perfect nanocube: Precise control of size, shape and composition 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 2ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 3ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 4ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 5ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells 6
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
(Date:7/9/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/98rrmr/biometrics_for ... "Biometrics for Banking; Market & Technology Analysis, Adoption ... offering. The adoption for banking purposes ... the forecast is that by 2020 it will ... in delivering biometric systems to the banking industry. ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... Denizens of oceans, lakes and even wet ... intricately patterned, glass-like shells. Curiously, these tiny phytoplankton could ... Diatoms build their hard cell walls by laying down ... key material of the semiconductor industrysilicon. If we can ...
... stem cells from mice, UT Southwestern Medical Center researchers ... importantly, functioning muscle cells in mice afflicted with ... study represents the first time transplanted embryonic stem cells ... in a model of muscular dystrophy. The researchers ...
... in French . , A study led ... between individuals at the DNA level can lead to ... in turn, are responsible for the vast array of ... of the Genome Regulators in Disease (GRID) Project funded ...
Cached Biology News:In diatom, scientists find genes that may level engineering hurdle 2Stem-cell transplantation improves muscles in MD animal model, UT Southwestern researchers report 2Stem-cell transplantation improves muscles in MD animal model, UT Southwestern researchers report 3Tiny genetic differences have huge consequences: McGill researchers 2
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
PA coated Agarose beads LPA Beads...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse monoclonal antibody to PAEP - progestagen-associated endometrial protein (placental protein 14, pregnancy-associated endometrial alpha-2-globulin, alpha uterine protein)...
Biology Products: